<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10332">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00671749</url>
  </required_header>
  <id_info>
    <org_study_id>US10066</org_study_id>
    <nct_id>NCT00671749</nct_id>
  </id_info>
  <brief_title>Combination Therapy With Differin® Gel 0.3% and Duac® (Clindamycin/Benzoyl Peroxide Gel) in Subjects With Acne Vulgaris</brief_title>
  <official_title>A Clinical Assessment of Combination Therapy With Differin® Gel, 0.3% With Duac® (Clindamycin/Benzoyl Peroxide Gel) in Subjects With Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma Laboratories, L.P.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma Laboratories, L.P.</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to determine the efficacy and safety of 12 week treatment with Differin® Gel
      0.3% applied in the evening, in combination with Duac® (Clindamycin/Benzoyl Peroxide Gel)
      applied in the morning, in Subjects with Acne vulgaris.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Same as above.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percent Change From Baseline in Total Lesion Counts</measure>
    <time_frame>6 and 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Global Severity Assessment Success</measure>
    <time_frame>6 and 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Global Severity was assessed on a 6 point scale (Clear, Almost Clear, Mild, Moderate, Severe). The scale was dichotomized to success or failure where success = Clear or Almost Clear</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Assessment of Improvement From Baseline</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Worst Post Baseline Tolerability Assessment - Erythema</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Please Note: &quot;Tolerability Assessments&quot; were captured separately from adverse events. Tolerability changes that required a dose modification or concomitant treatment were to be recorded on the Adverse Event CRF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Worst Post Baseline Tolerability Assessment - Scaling</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Please Note: &quot;Tolerability Assessments&quot; were captured separately from adverse events. Tolerability changes that required a dose modification or concomitant treatment were to be recorded on the Adverse Event CRF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Worst Post Baseline Tolerability Assessment - Dryness</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Please Note: &quot;Tolerability Assessments&quot; were captured separately from adverse events. Tolerability changes that required a dose modification or concomitant treatment were to be recorded on the Adverse Event CRF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Worst Post Baseline Tolerability Assessment - Burning/Stinging</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Please Note: &quot;Tolerability Assessments&quot; were captured separately from adverse events. Tolerability changes that required a dose modification or concomitant treatment were to be recorded on the Adverse Event CRF.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Study Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>adapalene gel, 0.3%
Other Names:
Differin® Gel, 0.3% Applied once daily at bedtime
clindamycin/benzoyl peroxide gel
Other Names:
Duac® Gel Applied once daily in the morning</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>adapalene gel, 0.3%</intervention_name>
    <description>Applied once daily at bedtime</description>
    <arm_group_label>Study Treatment</arm_group_label>
    <other_name>Differin® Gel, 0.3%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clindamycin/benzoyl peroxide gel</intervention_name>
    <description>Applied once daily in the morning</description>
    <arm_group_label>Study Treatment</arm_group_label>
    <other_name>Duac® Gel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects with a minimum of 20 inflammatory lesions on the face;

          2. Subjects with a minimum of 15 and a maximum of 100 non-inflammatory lesions (open and
             closed comedones) on the face, excluding the nose;

          3. Subject has a Global Severity Assessment

        Exclusion Criteria:

        1. Subjects with more than three nodulo-cystic lesions
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ron W Gottschalk, MD</last_name>
    <role>Study Director</role>
    <affiliation>Galderma Laboratories, L.P.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Dermatology and Laser Surgery</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derm Research, P.L.L.C.</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brodell Medical</name>
      <address>
        <city>Warren</city>
        <state>Ohio</state>
        <zip>44483</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Cutaneous Research Specialists</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <lastchanged_date>February 16, 2016</lastchanged_date>
  <firstreceived_date>April 30, 2008</firstreceived_date>
  <firstreceived_results_date>August 12, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adapalene</mesh_term>
    <mesh_term>Benzoyl Peroxide</mesh_term>
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Clindamycin palmitate</mesh_term>
    <mesh_term>Clindamycin phosphate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Combination Therapy</title>
          <description>Each subject applied each of the study medications once daily: Duac® Topical Gel in the morning and Differin® Gel, 0.3% in the evening.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="92"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Combination Therapy</title>
          <description>Each subject applied each of the study medications once daily: Duac® Topical Gel in the morning and Differin® Gel, 0.3% in the evening.</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="100"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="18.2" spread="5.40"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="56"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="44"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>American Indian or Alaska Native</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Native Hawaiian or Other Pacific Islander</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black or African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="77"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>More than one race</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Not Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="93"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Duration of Acne</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="4.0" spread="3.91"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Fitzpatrick Skin Type</title>
          <description>Investigator assessment based on the standard Fitzpatrick Skin Test (Scale I to VI). Example:
TYPE 1: Highly sensitive, always burns, never tans. TYPE 2: Very sun sensitive, burns easily, tans minimally. TYPE 3: Sun sensitive skin, sometimes burns, slowly tans to light brown. TYPE 4: Minimally sun sensitive, burns minimally, always tans to moderate brown.
TYPE 5: Sun insensitive skin, rarely burns, tans well. TYPE 6: Sun insensitive, never burns, deeply pigmented</description>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>I</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>II</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="27"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>III</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="38"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>IV</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="22"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>V</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>VI</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in Total Lesion Counts</title>
        <time_frame>6 and 12 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy</title>
            <description>Each subject applied each of the study medications once daily: Duac® Topical Gel in the morning and Differin® Gel, 0.3% in the evening.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="100"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent Change From Baseline in Total Lesion Counts</title>
            <units>Percent Change</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Week 6</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-47" spread="24.43"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 12</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-64" spread="24.07"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Global Severity Assessment Success</title>
        <description>Global Severity was assessed on a 6 point scale (Clear, Almost Clear, Mild, Moderate, Severe). The scale was dichotomized to success or failure where success = Clear or Almost Clear</description>
        <time_frame>6 and 12 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy</title>
            <description>Each subject applied each of the study medications once daily: Duac® Topical Gel in the morning and Differin® Gel, 0.3% in the evening.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="100"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Global Severity Assessment Success</title>
            <description>Global Severity was assessed on a 6 point scale (Clear, Almost Clear, Mild, Moderate, Severe). The scale was dichotomized to success or failure where success = Clear or Almost Clear</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Week 6</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 12</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="42"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Global Assessment of Improvement From Baseline</title>
        <time_frame>12 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy</title>
            <description>Each subject applied each of the study medications once daily: Duac® Topical Gel in the morning and Differin® Gel, 0.3% in the evening.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="100"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Global Assessment of Improvement From Baseline</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Clear</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Almost Clear</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="40"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Marked Improvement</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="27"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Moderate Improvement</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Minimal Improvement</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>No Change</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Worse</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Worst Post Baseline Tolerability Assessment - Erythema</title>
        <description>Please Note: &quot;Tolerability Assessments&quot; were captured separately from adverse events. Tolerability changes that required a dose modification or concomitant treatment were to be recorded on the Adverse Event CRF.</description>
        <time_frame>12 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Safety Population (n=99)</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy</title>
            <description>Each subject applied each of the study medications once daily: Duac® Topical Gel in the morning and Differin® Gel, 0.3% in the evening.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="99"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Worst Post Baseline Tolerability Assessment - Erythema</title>
            <description>Please Note: &quot;Tolerability Assessments&quot; were captured separately from adverse events. Tolerability changes that required a dose modification or concomitant treatment were to be recorded on the Adverse Event CRF.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>None</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="29"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Mild</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="37"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Moderate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="33"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Severe</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Worst Post Baseline Tolerability Assessment - Scaling</title>
        <description>Please Note: &quot;Tolerability Assessments&quot; were captured separately from adverse events. Tolerability changes that required a dose modification or concomitant treatment were to be recorded on the Adverse Event CRF.</description>
        <time_frame>12 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Safety Population (n=99)</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy</title>
            <description>Each subject applied each of the study medications once daily: Duac® Topical Gel in the morning and Differin® Gel, 0.3% in the evening.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="99"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Worst Post Baseline Tolerability Assessment - Scaling</title>
            <description>Please Note: &quot;Tolerability Assessments&quot; were captured separately from adverse events. Tolerability changes that required a dose modification or concomitant treatment were to be recorded on the Adverse Event CRF.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>None</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="53"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Mild</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="27"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Moderate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Severe</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Worst Post Baseline Tolerability Assessment - Dryness</title>
        <description>Please Note: &quot;Tolerability Assessments&quot; were captured separately from adverse events. Tolerability changes that required a dose modification or concomitant treatment were to be recorded on the Adverse Event CRF.</description>
        <time_frame>12 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Safety Population (n=99)</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy</title>
            <description>Each subject applied each of the study medications once daily: Duac® Topical Gel in the morning and Differin® Gel, 0.3% in the evening.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="99"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Worst Post Baseline Tolerability Assessment - Dryness</title>
            <description>Please Note: &quot;Tolerability Assessments&quot; were captured separately from adverse events. Tolerability changes that required a dose modification or concomitant treatment were to be recorded on the Adverse Event CRF.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>None</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="49"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Mild</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="27"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Moderate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Severe</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Worst Post Baseline Tolerability Assessment - Burning/Stinging</title>
        <description>Please Note: &quot;Tolerability Assessments&quot; were captured separately from adverse events. Tolerability changes that required a dose modification or concomitant treatment were to be recorded on the Adverse Event CRF.</description>
        <time_frame>12 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Safety Population (n=99)</population>
        <group_list>
          <group group_id="O1">
            <title>Combination Therapy</title>
            <description>Each subject applied each of the study medications once daily: Duac® Topical Gel in the morning and Differin® Gel, 0.3% in the evening.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="99"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Worst Post Baseline Tolerability Assessment - Burning/Stinging</title>
            <description>Please Note: &quot;Tolerability Assessments&quot; were captured separately from adverse events. Tolerability changes that required a dose modification or concomitant treatment were to be recorded on the Adverse Event CRF.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>None</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="67"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Mild</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Moderate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Severe</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 Weeks</time_frame>
      <desc>Please Note: &quot;Tolerability Assessments&quot; were captured separately from adverse events. Tolerability changes that required a dose modification or concomitant treatment were to be recorded on the Adverse Event CRF.</desc>
      <group_list>
        <group group_id="E1">
          <title>Combination Therapy</title>
          <description>Each subject applied each of the study medications once daily: Duac® Topical Gel in the morning and Differin® Gel, 0.3% in the evening.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application Site Burn</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Application Site Dryness</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Application Site Erythema</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Application Site Exfoliation</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Application Site Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Elizabeth M Nieman</name_or_title>
      <organization>Galderma Laboratories, L.P.</organization>
      <phone>817-961-5000</phone>
      <email>elizabeth.nieman@galderma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
